Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Aug 1;37(10):1519-1524.
doi: 10.1097/QAD.0000000000003611. Epub 2023 Jun 1.

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability

Zhanna Shubin  1   2 , Sherry Stanfield-Oakley  3 , Jiraporn Puangkaew  4 , Punnee Pitisutthithum  5 , Sorachai Nitayaphan  4 , Sanjay Gurunathan  6 , Faruk Sinangil  7 , Suwat Chariyalertsak  8   9 , Nittaya Phanuphak  10 , Julie A Ake  1 , Robert J O'Connell  1   4 , Sandhya Vasan  1   2 , Siriwat Akapirat  4 , Michael A Eller  1   2 , Guido Ferrari  3 , Dominic Paquin-Proulx  1   2 ; for the RV306 Study Group
Affiliations
Randomized Controlled Trial

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability

Zhanna Shubin et al. AIDS. .

Abstract

Objectives: The RV144 vaccine trial resulted in a decreased risk of HIV acquisition that was associated with a nonneutralizing antibody response. The objective of this study was to determine the impact of an additional boost to the RV144 vaccine regimen on antibody effector function and durability.

Design: RV306 was a randomized, double-blind late boosting of the RV144 prime-boost regimen in HIV-uninfected Thai adults (NCT01931358). This analysis included study participants who received the RV144 vaccine regimen and received no additional boost (group 1) or were boosted with ALVAC-HIV and AIDSVAX (group 2) or only AIDSVAX alone (group 3) 24 weeks after completing the RV144 series.

Methods: Plasma samples from RV306 study participants were used to measure antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP), antibody-dependent complement deposition (ADCD), antibody-dependent cellular cytotoxicity (ADCC), trogocystosis, and gp120-specifc IgG subclasses.

Results: Additional boosting increased the magnitude of all Fc-mediated effector functions 2 weeks following the additional boost compared with 2 weeks after completing the RV144 regimen. However, only trogocytosis remained higher 24-26 weeks after the last vaccination for the study participants receiving an additional boost compared with those that did not receive an additional boost. The additional boost increased IgG1 and IgG4 but decreased IgG3 gp-120 specific antibodies compared with 2 weeks after completing the RV144 regimen.

Conclusion: Additional boosting of RV144 improved the magnitude but not the durability of some Fc-mediated effector functions that were associated with vaccine efficacy, with trogocytosis being the most durable.

PubMed Disclaimer

Conflict of interest statement

S.G. is an employee and shareholder of Sanofi Pasteur. F.S. is an employee of Global Solutions for Infectious Diseases. All other authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Peak levels of Fc-mediated effector function are increased following an additional boost to the RV144 vaccine regiment.
Fig. 2
Fig. 2
IgG subclass binding titer to gp120.
See this image and copyright information in PMC

References

    1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. . MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209–2220. - PubMed
    1. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. . Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275–1286. - PMC - PubMed
    1. Gorini G, Fourati S, Vaccari M, Rahman MA, Gordon SN, Brown DR, et al. . Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. PLoS Pathog 2020; 16:e1008377. - PMC - PubMed
    1. Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, et al. . HIV vaccine candidate activation of hypoxia and the inflammasome in CD14(+) monocytes is associated with a decreased risk of SIV(mac251) acquisition. Nat Med 2018; 24:847–856. - PMC - PubMed
    1. Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, et al. . Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat Commun 2017; 8:15711. - PMC - PubMed

Publication types

Associated data